answer text |
<p><del class="ministerial">No assessment has been made.</del> The Medicines and Healthcare
products Regulatory Agency (MHRA) is a largely fee charging regulator with approximately
three quarters of its income derived from fees levied on applicants. This is a standard
form of cost recovery for regulators worldwide. The MHRA has recently concluded a
public consultation on its statutory fees to ensure all costs involved in delivery
are recovered, which concluded on 23 November 2022.</p>
|
|